Abbott’s stock (NYSE: ABT) lost more than 27% – dropping from $87 at the beginning of the year to below $63 in late March – then spiked 58% to around $100 now. That means it is well above the levels where it started the year. Why? Abbott secured regulatory approval for Covid-19 testing as early as..
Source: Forbes Markets
